Zydus Lifesciences launches generic drug for overactive bladder in US market

Zydus is among the first suppliers to launch the generic version of Mirabegron extended-release tablets (USP 25 mg) in the US market. The company is also preparing to launch the 50 mg tablets in the market. Mirabegron is indicated for the treatment of Overactive Bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3uByqxE
via IFTTT